Wednesday, February 10, 2010, 2:22am EST - Canadian Markets open in 7 hours and 8 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Neurocrine Biosciences Inc. (NBIX)

 On Feb 9: 2.37 USD  Up 0.01 (0.42%)  
MORE ON NBIX
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Neurocrine Biosciences, Inc. (NasdaqNM:NBIX) Delayed quote dataEdit
After Hours: 2.37 0.00 (0.00%) as of 4:34pm EST on 02/09/10
Last Trade: 2.37 USD
Trade Time: Feb 9
Change: Up 0.01 (0.42%)
Prev Close: 2.36
Open: 2.39
Bid: 1.48 x 100
Ask: 3.32 x 100
1y Target Est: 3.67
Day's Range: 2.34 - 2.41
52wk Range: 1.94 - 4.25
Volume: 68,616
Avg Vol (3m): 188,943
Market Cap: 92.92M
P/E (ttm): N/A
EPS (ttm): -1.85
Div & Yield: N/A (N/A%)
Neurocrine Biosciences Inc. (NBIX)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add NBIX to Portfolio   Download Data

HEADLINES
• NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of I
EDGAR Online (Tue 2:17pm)
• Neurocrine names CEO of Receptos to its board
AP (Mon, Feb 8)
• Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
PRNewswire (Mon, Feb 8)
• New Star Analyst Rankings for Neurocrine Biosciences, Inc.
StarMine (Thu, Feb 4)
• Neurocrine Biosciences Inc. Q4 2009 Earnings Call Transcript
at Seeking Alpha (Wed, Feb 3)
• NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Wed, Feb 3)
• Neurocrine Biosciences Reports Fourth Quarter and Year-End 2009 Results
PRNewswire (Wed, Feb 3)
• Q4 2009 Neurocrine Biosciences, Inc. Earnings Release - After Market Close
CCBN (Wed, Feb 3)
• Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results
PRNewswire (Wed, Jan 27)
• Neurocrine Advances VMAT2 Inhibitor Program
PRNewswire (Mon, Dec 21)
More Headlines for NBIX...
ANALYST
EPS Est (next year) (Dec-10) : -0.81
EPS Est (in 2 years) (Dec-11) : -0.91
Avg Rec (current)*: 2.7
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices